Previous 10 | Next 10 |
LA JOLLA, Calif., Jan. 14, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL) , a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate the endocannabinoid system, today reported financial and operating results for the first qua...
Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks, and our single stock focus. If you are interested in listening to Stocks To Watch t...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
The following slide deck was published by Artelo Biosciences, Inc. in conjunction with this Read more ...
LA JOLLA, Calif., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL ) , a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate the endocannabinoid system, today announced the appointment of seasoned in...
Artelo Biosciences (NASDAQ: ARTL ): FY GAAP EPS of -$1.46 misses by $0.13 . More news on: Artelo Biosciences, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
LA JOLLA, Calif., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL) , a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate the endocannabinoid system, today reported financial and operating results for the fourth qu...
Gainers: EyeGate Pharmaceuticals (NASDAQ: EYEG ) +43% . More news on: EyeGate Pharmaceuticals, Inc., Stage Stores, Inc., Cancer Genetics, Inc., Stocks on the move, Read more ...
LA JOLLA, Calif., Nov. 18, 2019 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL) , a clinical stage biopharmaceutical company developing therapeutics that modulate the endocannabinoid system, announced today that positive non-clinical data with the Company’s Fatty Aci...
LA JOLLA, Calif., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL) , a clinical stage biopharmaceutical company developing therapeutics that modulate the endocannabinoid system, today announced that it will be presenting at the Annual Investival Showcase to be ...
News, Short Squeeze, Breakout and More Instantly...
Artelo Biosciences Inc. Company Name:
ARTL Stock Symbol:
OTCMKTS Market:
Artelo Biosciences Inc. Website:
ART26.12 seeks to address a critical need in painful neuropathies, including chemotherapy-induced peripheral neuropathy for which there is no FDA-approved treatment Phase 1 trial results expected in the first half of 2025 SOLANA BEACH, Calif., July 15, 2024 (GLOBE NEWSWIRE) -- A...
SOLANA BEACH, Calif., July 03, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological condit...
Inhibition of FABP5 Demonstrates Activity in Cancer, Psoriasis, and Anxiety Disorders Results from Several Research Studies Presented at the Annual ICRS Symposium SOLANA BEACH, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a c...